Sichuan Biokin Pharmaceutical Co., Ltd.SSE: 688506

Announcement on Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase III Clinical Trial of T-Bren for Injection (HER2 ADC) for the Treatment of HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · · 2 pages · Chinese

On 6ix: 6ix.com/news/sichuan-biokin-pharmaceutical-co-ltdannouncement-on-voluntary-disclosure-of-the-completion-of-enrollment-of-the-first-subject-in-the-phase-iii-clinical-trial-of-t-bren-for-injection-her2-adc-for-the-treatment-of-her2-expressing-platinum-resistant-recurrent-epithelial-ovarian-cancer-fallopian-tube-cancer-and-primary-peritoneal-cancer

Release

Announcement on Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase III Clinical Trial of T-Bren for Injection (HER2 ADC) for the Treatment of HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Sichuan Biokin Pharmaceutical Co., Ltd. on 6ix

Earlier from Sichuan Biokin Pharmaceutical

Later from Sichuan Biokin Pharmaceutical

All Sichuan Biokin Pharmaceutical news releases